Perforating dermatosis in a young female patient receiving adalimumab biosimilar CTP-17 for chronic plaque psoriasis: A case report
Alessia Lozito, Silvia Baravalle, Gabriele Poddine, Chiara Colato, Antonio Carletto, Elena Fracassi, Francesco Bellinato, Giampiero Girolomoni, Paolo Gisondi · 2025
Read Perforating dermatosis in a young female patient receiving adalimumab biosimilar CTP-17 for chronic plaque psoriasis: A case report by Alessia Lozito, Silvia Baravalle, Gabriele Poddine, Chiara Colato, Antonio Carletto, Elena Fracassi, Francesco Bellinato, Giampiero Girolomoni, Paolo Gisondi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12696279.txt.
Description
Alessia Lozito and eight co-authors reported in 2025 a rare skin reaction in a young woman treated with a biosimilar of adalimumab for plaque psoriasis. After switching products she developed painful, ulcerated plaques on her thighs, buttocks and elbows. Tests confirmed acquired perforating dermatosis, a condition where damaged collagen pushes through the skin. No usual triggers such as diabetes or kidney failure were present.
Stopping the drug and giving four weeks of steroid treatment cleared the lesions fully. Her psoriasis and joint disease were later managed with other medicines. The authors suggest the reaction may stem from disturbed fibronectin or sugar-damaged proteins unsettling skin cells. They urge doctors to count this reaction among the rare harms of this drug class. Early recognition and withdrawal can stop it worsening, they note.
Catalog record
| CREATOR | Alessia Lozito, Silvia Baravalle, Gabriele Poddine, Chiara Colato, Antonio Carletto, Elena Fracassi, Francesco Bellinato, Giampiero Girolomoni, Paolo Gisondi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 9 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |